Jaguar Health (JAGX) Non-Current Assets (2014 - 2026)
Jaguar Health (JAGX) posted quarterly Non-Current Assets of $17.2 million for Q1 2026, down 18.06% year-over-year from $21.0 million in Q1 2025, and up 205.38% quarter-over-quarter from -$16.3 million in Q4 2025.
Jaguar Health (JAGX) Non-Current Assets (2014 - 2026) Analysis & Trends
Jaguar Health (JAGX) has reported Non-Current Assets for 13 consecutive years, with $17.2 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Non-Current Assets fell 18.06% year-over-year to $17.2 million; the TTM figure through Mar 2026 stood at $41.3 million (down 51.63% YoY), while the FY2025 annual figure was -$16.3 million, down 177.0% from the prior year.
- Non-Current Assets climbed to $17.2 million in Q1 2026 per JAGX's latest filing, from -$16.3 million in the prior quarter.
- Across five years, Non-Current Assets topped out at $26.5 million in Q2 2022 and bottomed at -$16.3 million in Q4 2025.
- Historically, Non-Current Assets has averaged $20.3 million across 5 years, with a median of $21.8 million in 2024.
- Annual changes were most pronounced in 2022 — Non-Current Assets grew 5.06% — and 2025, when it tumbled 177.0%.
- Jaguar Health's Non-Current Assets stood at $25.1 million in 2022, then declined by 9.28% to $22.8 million in 2023, then dropped by 6.9% to $21.2 million in 2024, then sank by 177.0% to -$16.3 million in 2025, then surged by 205.38% to $17.2 million in 2026.
- Business Quant data shows JAGX's Non-Current Assets at $17.2 million in Q1 2026, -$16.3 million in Q4 2025, and $20.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.93 Bn | 131.08 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 86.11 Bn | 78.11 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 65.43 Bn | 60.25 Bn | 1.37 Bn | 1.96 Bn |
| 4 | Moderna | 56.09 Bn | 50.96 Bn | 52.00 Mn | 5.15 Bn |
| 5 | BeOne Medicines | 42.13 Bn | 37.03 Bn | 1.53 Bn | 1.96 Bn |
| 6 | Alnylam Pharmaceuticals | 31.61 Bn | 28.30 Bn | 992.69 Mn | 938.60 Mn |
| 7 | BioNTech SE | 27.68 Bn | 9.29 Bn | 668.28 Mn | 6.80 Bn |
| 8 | Insmed | 27.49 Bn | 26.32 Bn | 358.27 Mn | 468.65 Mn |
| 9 | Royalty Pharma | 27.36 Bn | 26.52 Bn | - | 18.06 Bn |
| 10 | Jaguar Health | 442,700.83 | -9.62 Mn | 19.11 Mn | 17.22 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 17.22 Mn |
| Dec 31, 2025 | -16.35 Mn |
| Sep 30, 2025 | 20.07 Mn |
| Jun 30, 2025 | 20.37 Mn |
| Mar 31, 2025 | 21.02 Mn |
| Dec 31, 2024 | 21.23 Mn |
| Sep 30, 2024 | 21.82 Mn |
| Jun 30, 2024 | 21.35 Mn |
| Mar 31, 2024 | 21.68 Mn |
| Dec 31, 2023 | 22.80 Mn |
| Sep 30, 2023 | 23.32 Mn |
| Jun 30, 2023 | 23.95 Mn |
| Mar 31, 2023 | 24.57 Mn |
| Dec 31, 2022 | 25.13 Mn |
| Sep 30, 2022 | 26.08 Mn |
| Jun 30, 2022 | 26.52 Mn |
| Mar 31, 2022 | 24.43 Mn |
| Dec 31, 2021 | 24.83 Mn |
| Sep 30, 2021 | 35.25 Mn |
| Jun 30, 2021 | 25.25 Mn |